Regulation of placenta growth factor by hemodynamics and reactive oxygen species

血流动力学和活性氧对胎盘生长因子的调节

基本信息

批准号：
8492141
负责人：
PAMELA C LOVERN
金额：
$ 34.67万
依托单位：
OKLAHOMA STATE UNIVERSITY STILLWATER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-07-17 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8492141
关键词：
Accounting Affect American Animal Model Animals Arteries Biological Biological Models Blood Vessels Blood flow Bypass Cardiovascular Diseases Cardiovascular system Cell Culture System Cell Culture Techniques Cells Cellular biology Clinical Clinical Research Coculture Techniques Combined Modality Therapy Complex Complications of Diabetes Mellitus Coronary Coronary Arteriosclerosis Data Defect Development Diabetes Mellitus Diagnosis Diet Disease Distal Dose Endothelial Cells Epoprostenol Experimental Models Fatty acid glycerol esters Functional disorder Future Generations Goals Growth Growth Factor Hydrogen Peroxide Hyperglycemia Hyperlipidemia In Vitro Knowledge Link Literature Measurement Measures Mediator of activation protein Messenger RNA Metabolic Metabolic syndrome Molecular Molecular Biology Mus Nitric Oxide Outcome Oxidative Stress Patients Peripheral arterial disease Physiological Physiological Processes Placental Growth Factor Positioning Attribute Production Proteins Reactive Oxygen Species Regulation Research Risk Role Signal Pathway Signal Transduction Smooth Muscle Myocytes Streptozocin Techniques Testing Therapeutic Therapeutic Intervention Time Tissues Vascular Diseases Vascular Endothelial Cell Vascular Endothelial Growth Factors Work artery occlusion base design diabetic diabetic cardiomyopathy diabetic patient functional improvement hemodynamics improved in vivo in vivo Model innovation mortality mouse model mutant mouse model novel public health relevance research study response shear stress

项目摘要

DESCRIPTION (provided by applicant): Collateral artery enlargement (arteriogenesis) is a physiological process that can 'bypass' atherosclerotic supply arteries to preserve blood flow to distal tissue. Thus, pharmacological stimulation of arteriogenesis could be highly beneficial in the treatment of ischemic vascular diseases, such as coronary artery disease (CAD) and peripheral artery disease (PAD). Such treatments would be especially valuable in the setting of diabetes, which both 1) severely increases the risk of CAD and PAD and 2) inhibits native (unstimulated) arteriogenesis. Placenta growth factor (PlGF, PGF) is a VEGF-related growth factor that specifically favors the expansion of arteries via arteriogenesis. Thus, therapeutic stimulation of PlGF expression could potentially be used to enhance arteriogenesis and improve clinical outcomes in patients with CAD and PAD. However, such treatments are not currently possible, due to a lack of understanding of the basic mechanism(s) regulating PlGF expression. Our preliminary data suggests the existence of a novel mechanism regulating PlGF expression in the vascular wall. Moreover, our evidence suggests that this mechanism is dysfunctional in diabetes. Thus, dysregulation of PlGF expression may contribute to faulty arteriogenesis in diabetics. The LONG TERM GOAL of this research is to elucidate key mechanisms regulating PlGF expression under physio- and patho-physiological conditions. This project will pursue three Specific Aims. Specific Aim 1: Establish the basic regulatory mechanism controlling PlGF expression in the vascular wall. These studies will be performed in three complementary model systems: primary vascular smooth muscle cells (SMC) in static culture; co- cultured vascular endothelial cells (EC) and SMC which are exposed to shear stress; and isolated perfused mouse vessels. Specific Aim 2: Identify key steps in the basic PlGF regulatory mechanism that are altered by diabetes. These studies will confirm the physiological relevance of the mechanism(s) uncovered in Aim 1. These experiments will be conducted in mouse models of hyperglycemia (streptozotocin treatment), hyperlipidemia (high-fat diet treatment) and combined hyperglycemia/hyperlipidemia. This design will allow us 1) to determine what facet of the complex metabolic dysfunction that typically occurs in diabetes inhibits PlGF expression, and 2) to pinpoint the regulatory step at which inhibition of PlGF expression occurs. Specific Aim 3: Assess the ability of enhanced endogenous PlGF expression to stimulate arteriogenesis. These studies will take the results of Aim 2 to the next level by determining whether correction of the signaling defect revealed in Aim 2 can 1) reverse the inhibition of PlGF expression in diabetes, and 2) result in functional improvement as measured by capacity to undergo arteriogenesis in response to vascular occlusion. These innovative and novel studies will provide essential new information about the regulation of an important arteriogenic factor and will provide "proof of concept" for the idea that normalizing or enhancing PlGF expression can improve the arteriogenic response to vascular occlusion (due to CAD or PAD) in patients with diabetes.

描述（由申请人提供）：侧支动脉扩大（动脉生成）是一个生理过程，可以绕过动脉粥样硬化的供应动脉，以保留血液流向远端组织的血液。因此，对动脉生成的药理刺激可能对治疗缺血性血管疾病（例如冠状动脉疾病（CAD）和周围动脉疾病（PAD））非常有益。这种治疗在糖尿病的环境中尤其有价值，这两者既有1）严重增加了CAD和PAD的风险以及2）抑制天然（未刺激的）动脉生成。胎盘生长因子（PLGF，PGF）是与VEGF相关的生长因子，它特异性地利用动脉生成的动脉扩张。因此，可以使用治疗性PLGF表达刺激来增强动脉生成并改善CAD和PAD患者的临床结局。但是，由于缺乏对调节PLGF表达的基本机制的了解，目前无法进行此类处理。我们的初步数据表明存在一种新的机制，该机制调节了血管壁中的PLGF表达。此外，我们的证据表明，这种机制在糖尿病中是功能失调。因此，PLGF表达的失调可能导致糖尿病患者动脉生成错误。这项研究的长期目标是阐明在生理和病理生理条件下调节PLGF表达的关键机制。该项目将追求三个具体目标。具体目标1：建立控制PLGF表达在血管壁中的基本调节机制。这些研究将在三个互补模型系统中进行：静态培养中的原发血管平滑肌细胞（SMC）；暴露于剪切应力的共同培养的血管内皮细胞（EC）和SMC；和孤立的灌注小鼠血管。特定目标2：确定糖尿病改变的基本PLGF调节机制中的关键步骤。这些研究将确认AIM 1中发现的机制的生理相关性。这些实验将在高血糖（链唑辛治疗），高脂血症（高脂饮食治疗）和联合性高血糖/高血糖/高脂血症的小鼠模型中进行。该设计将使我们1）确定通常发生在糖尿病中的复杂代谢功能障碍的哪个方面会抑制PLGF表达，而2）查明抑制PLGF表达的调节步骤。特定目标3：评估增强的内源性PLGF表达刺激动脉生成的能力。这些研究将通过确定AIM 2中的校正AIM 2的结果将AIM 2的结果提升到一个新的水平，而AIM 2中显示的信号缺陷是否可以1）扭转糖尿病中PLGF表达的抑制作用，而2）结果可改善功能改善，如通过对血管闭塞的响应进行动脉生成的能力来衡量的。这些创新和新颖的研究将提供有关重要的动脉生成因子调节的重要新信息，并将为糖尿病患者的血管闭塞（CAD或PAD）改善对血管闭塞（CAD或PAD）的动脉原性反应的想法提供“概念证明”。